Abstract
AbstractThe advent of small molecule inhibitors of B-cell receptor (BCRi) signaling has revolutionized the therapy for patients with chronic lymphocytic leukemia (CLL). These therapies have largely supplanted cytotoxic chemotherapy for both untreated and relapsed disease.1,2 The Bruton’s tyrosine kinase (BTK) inhibitors, ibrutinib and acalabrutinib, have demonstrated high rates of durable responses and prolonged progression free survival (PFS) and are approved for the treatment of previously untreated or relapsed CLL.3–11 Zanubrutinib, which is already approved for mantle cell lymphoma,12 is likely to gain approval for CLL in the near future, and there are other BTKi inhibitors including noncovalent BTKis that are currently in development.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call